DGAP-News: Expedeon AG: Expedeon AG adds ELISA-ONE(TM) next generation cell signalling assay technology to product offering

PRESS RELEASE
08 May 2019

Expedeon AG adds ELISA-ONE(TM) next generation cell signalling assay technology to product offering

Technology developed by Expedeon company TGR BioSciences

Heidelberg, Germany and Cambridge, UK, 08 May 2019 - Expedeon AG (Frankfurt: EXN; ISIN: DE000A1RFM03; Prime Standard) announced it has added ELISA-ONE(TM) to its product offering. The technology was developed by TGR BioSciences, which was acquired by Expedeon in May 2018.

This product enables Expedeon to address new markets, such as the cell signalling market, at a critical time in the company's growth and development. The cell signalling market was reported to be USD 2.53 billion in 2017 and is forecast to reach USD 3.51 billion by 2022 at a CAGR of 6.8%.^[1] The immunoassay market was estimated to be USD $1.6 to $1.7 billion in 2017 according to multiple reports. Amongst the market segments analysed, ELISA was found to be the most widely conducted immunoassay procedure according to one survey with the majority of users focusing on immunology, molecular biology, cell biology, biochemistry and cell signalling.² From this we could estimate that the addressable market for the ELISA-ONE is in the range of $300 million USD.

ELISA-ONE(TM) next generation ready-to-use ELISA kits have been developed for fast detection of key intracellular proteins in major signalling pathways. Monitoring cell signalling pathways is essential for understanding many cellular processes and disease states and is therefore vital to help further basic research and drug discovery.

Immunoassays are a gold-standard method for the detection of proteins and biomarkers in discovery processes. However, onerous multi-step and error-prone traditional ELISA protocols limit throughput and data consistency, creating a critical bottleneck and significantly impeding the transfer of assays from development into high-throughput screens.

Additionally, researchers investigating intracellular proteins in signalling pathways often face further challenges with limited availability of, and unoptimized or unvalidated, antibody pairs. Powered by Expedeon's CaptSure(TM) technology, ELISA-ONE(TM) kits provide all reagents and optimized antibody pairs in one ready-to-use kit. This will save researchers valuable time, eliminating the need to evaluate different antibodies and offering a simplified solution for performing ELISA assays. The whole protocol takes less than 90 minutes, with far fewer handling steps than traditional ELISA methods.

Dr Heikki Lanckriet, CEO of Expedeon, said: "The addition of the ELISA-ONE(TM) technology to the Expedeon offering further integrates the Expedeon product portfolio, enriching the value for our customers' daily research work. This technology provides a solution to the most common issues that many researchers face, whilst maintaining the sensitivity they need in order to produce data they can trust. The addition of this kit to our portfolio supports our contribution to expediting cancer biomarker research, which is vital to the global effort to identify successful treatments and cures."

For further information, please contact:

Expedeon AG
Dr. Heikki Lanckriet
CEO/CSO
Phone: +44 1223 873 364
Email: heikki.lanckriet@expedeon.com
Investor website: www.investors.expedeon.com

MC Services AG (Investor Relations and International Media Relations)
Raimund Gabriel
Managing Partner
Phone: +49 89 210228 0
Email: expedeon@mc-services.eu

About Expedeon AG: www.expedeon.com
Expedeon is an enabler of exciting advances in medical science and patient care. The Company's core technologies, innovative products and services are used in research laboratories around the world, enabling scientists to push the boundaries of research and product development, and play an integral part in new diagnostic tools being brought to market. With applications spanning the entire workflows in genomics, proteomics and immunology, Expedeon's technologies both accelerate and simplify research and make new and cost-effective processes available to biopharmaceutical and diagnostic organisations alike, thereby underpinning its customers' development and commercialisation objectives. Expedeon's products are sold through a direct sales force and several distribution partners in Europe, the USA and Asia. Expedeon AG has offices in Germany, Spain, UK, USA and Singapore. The Company is listed on the Prime Standard segment of the Frankfurt Stock Exchange (Ticker: EXN; ISIN: DE000A1RFM03).

### This publication is intended for information only and constitutes neither an offer to sell nor an invitation to buy securities. Some statements included in this press release, relating neither to proven financial results nor other historical data, should be viewed as forward-looking, i.e. not definite. Such statements are mainly predictions of future results, trends, plans or goals. These statements should not be considered to be total guarantees since given their very nature they are subject to known and unknown risks and imponderability and can be affected by other factors as a consequence of which the actual results, plans and goals of Expedeon AG may deviate greatly from the established conclusions or implied predictions contained in such statements. Expedeon does not undertake to publicly update or revise these statements in the light of new information or future results or for any other reason. ###^[1] Cell Signalling Market, Markets and Markets, global forecast to 2022
2 2018 Immunoassay market overview, Biocompare, https://www.biocompare.com/Editorial-Articles/348411-Survey-Sizes-Up-Immunoassay-Market/